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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) 
is a significant pathogen in critically ill patients. 
In a nationwide surveillance study of United 
States hospitals, S. aureus was responsible for 
20% of nosocomial bloodstream infections, with 
an alarming increase in MRSA isolates more than 
doubling from 22% to 57% over the period from 
1995 to 2001.1 In critically ill patients, MRSA 
bacteremia is associated with a 22.1% higher 
attributable mortality rate compared with methi-
cillin-sensitive S. aureus.2 S. aureus is isolated in 
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Abstract
Background: While vancomycin loading doses may facilitate earlier pharmacokinetic–
pharmacodynamic target attainment, the impact of loading doses on clinical outcomes 
remains understudied. Critically ill patients are at highest risk of morbidity and mortality from 
methicillin resistant Staphylococcus aureus (MRSA) infection and hypothesized to most likely 
benefit from a loading dose. We sought to determine the association between receipt of a 
vancomycin loading dose and clinical outcomes in a cohort of critically ill adults.
Methods: Four hundred and forty-nine critically ill patients with MRSA cultures isolated 
from blood or respiratory specimens were eligible for the study. Cohorts were established 
by receipt of a loading dose (⩾20 mg/kg actual body weight) or not. The primary outcome 
was clinical failure, a composite outcome of death within 30 days of first MRSA culture, blood 
cultures positive ⩾7 days, white blood cell count up to 5 days from vancomycin initiation, 
temperature up to 5 days from vancomycin initiation, or substitution (or addition) of another 
MRSA agent.
Results: There was no difference in the percentage of patients experiencing clinical failure 
between the loading dose and no loading dose groups (74.8% versus 72.8%; p = 0.698). 
Secondary outcomes were also similar between groups, including mortality and acute kidney 
injury, as was subgroup analysis based on site of infection. Exploratory analyses, including 
assessment of loading dose based on quartiles and a multivariable logistic regression model 
showed no differences.
Conclusion: Use of vancomycin loading doses was not associated with improved clinical 
outcomes in critically ill patients with MRSA infection.
Keywords: critical care, infection, loading dose, methicillin resistant Staphylococcus aureus 
(MRSA), vancomycin
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approximately one out of every five cases of venti-
lator-associated pneumonia, with approximately 
56% MRSA isolates.3
Recent data suggest that inadequate attainment of 
a therapeutic vancomycin area-under-the-curve 
(AUC) to minimum inhibitory concentration 
(MIC) ratio on days 1 and 2 of therapy in MRSA 
bacteremia is associated with treatment failure.4 
Critically ill patients commonly receive significant 
fluid resuscitation and experience fluid shifts from 
the intravascular to the extravascular compart-
ment, which increases the volume of distribution 
(Vd) for hydrophilic drugs such as vancomycin.5,6 
Accordingly, recently updated consensus guide-
lines on vancomycin state that a loading dose of 
20–35 mg/kg actual body weight (not to exceed 
3000 mg) can be considered for critically ill patients 
with suspected or confirmed MRSA infection in 
order to ensure rapid attainment of appropriate 
serum concentrations.7 However, this recommen-
dation is limited by moderate strength of recom-
mendation (B) and quality of evidence (II), and is 
primarily based on pharmacokinetic outcomes 
rather than a documented clinical benefit.7
In a recent survey of practitioners regarding van-
comycin dosing in critically ill patients assessing 
self-reported consensus guideline compliance, use 
of loading doses for a variety of clinical scenarios 
was highly variable, with respondents often citing 
the lack of evidence for the clinical decision to 
forgo a loading dose, followed by concerns of 
nephrotoxicity.8 Given that critically ill patients 
are particularly vulnerable to poor outcomes from 
MRSA infection and exhibit altered pharmacoki-
netics of vancomycin that may place them at risk 
of missing identified pharmacokinetic–pharmaco-
dynamic targets, they are logically the population 
to gain the most benefit from loading doses of 
vancomycin. As such, we sought to determine 
whether critically ill patients with MRSA infection 
demonstrated improved clinical outcomes when 
receiving vancomycin loading doses (versus not) in 
order to provide needed clinical data to augment 
the pharmacokinetic outcomes previously assessed 
in studies of vancomycin loading doses.
Material and methods
Study design
This was a single center, retrospective cohort 
study of critically ill patients admitted to any 
intensive care unit (ICU) from January 2008 to 
October 2016 within a 865-bed tertiary academic 
medical center that serves as a referral center for 
the state and surrounding regions. Patients were 
included in the study if they had a positive res-
piratory or blood culture for MRSA and had van-
comycin initiated for MRSA during or up to 48 h 
before an ICU admission. Exclusion criteria were 
as follows: weight ⩾125 kg, any MRSA culture 
other than from blood or respiratory source, 
<1000 colony forming units/ml or 1–2% MRSA 
on respiratory cultures, loading dose information 
missing (i.e. from outside hospital), or if vanco-
mycin was started >48 h prior to the ICU admis-
sion. We elected to study pneumonia and 
bacteremia given the frequency of these infections 
in critically ill patients and their relative degree of 
morbidity compared with other infections (i.e. 
skin and soft tissue) in an attempt to prognosti-
cally enrich the study for patients that might clini-
cally benefit from a loading dose of vancomycin.9 
A weight of ⩾125 kg was excluded so as not to 
confound the assessment of loading doses on a 
milligram per kilogram of actual body weight 
basis. Patients were classified into two cohorts 
based on their initial vancomycin dose received: 
loading dose (⩾20 mg/kg actual body weight) or 
no loading dose (<20 mg/kg actual body weight).
The primary outcome was clinical failure, defined 
as a composite outcome with similar definitions 
to prior studies of MRSA infection,10,11 which 
included: death within 30 days of first MRSA cul-
ture, blood cultures positive ⩾7 days, white blood 
cell (WBC) count >12 × 103/mm3 up to 5 days 
from vancomycin initiation, temperature 
>100.4°F up to 5 days from vancomycin initia-
tion, or substitution (or addition) of another tar-
geted anti-MRSA antibiotic such as daptomycin, 
linezolid, or ceftaroline. The primary outcome 
was adjudicated in the order of the outcomes 
stated above, thus while some patients may have 
had more than one definition of clinical failure, 
each patient was classified with only one of the 
definitions based on the sequential order assessed.
Secondary outcomes included all-cause mortality 
in the ICU, time from vancomycin initiation to 
ICU discharge, acute kidney injury (AKI) within 
5 days of vancomycin initiation as assessed by the 
serum creatinine component of the Kidney 
Disease Improving Global Outcomes criteria,12 
first vancomycin serum trough concentration, and 
duration of vasopressor support, if applicable. 
AH Flannery, KL Wallace et al.
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Data were extracted from the electronic data 
warehouse and manual chart review was per-
formed on all included patients to ensure integrity 
of the data. Data were collected on patients to 
ensure comparability at baseline, including poten-
tial factors hypothesized by the investigators as 
being associated with receipt of a loading dose 
including severity of illness assessments such as 
Sequential Organ Failure Assessment score 
(SOFA)13 and Pitt bacteremia score (PBS),14,15 
need for mechanical ventilation or vasopressor 
support at the time of vancomycin initiation, hos-
pital service (classified into medical or surgical 
ICUs), history of kidney disease, and kidney func-
tion at the time of vancomycin initiation. 
Vancomycin MICs were determined per Clinical 
and Laboratory Standards Institute standards by 
broth microdilution via automated susceptibility 
testing methods with the Phoenix™ Automated 
Microbiology System (BD Diagnostics, Sparks, 
MD, USA) from January 2008 to October 2013 
and April 2016 to October 2016 and Etest (bio-
Mérieux, Marcy l’Etoile, France) from November 
2013 to March 2016. Receipt of concurrent 
nephrotoxins within 5 days of receiving the load-
ing dose was classified as the receipt of any of the 
following: angiotensin converting enzyme inhibi-
tors, angiotensin receptor blockers, intravenous 
(IV) acyclovir, aminoglycosides, amphotericin B, 
colistin, foscarnet, non-steroidal anti-inflamma-
tory drugs, polymyxin B, sulfamethoxazole/tri-
methoprim, IV tacrolimus, and piperacillin/
tazobactam. The study was approved by the 
Institutional Review Board at the University of 
Kentucky (#54961) with a waiver of informed 
consent given the study design.
Statistical analysis
Based on prior studies of MRSA infections sug-
gesting clinical failure rates as high as 41%,10,11 
and assuming a higher percentage due to the 
requirement for critical illness in our study, we 
anticipated a baseline clinical failure of 60%. In 
order to detect a 20% decrease in the clinical fail-
ure, we determined that 97 patients were required 
in each group (194 patients in total) to achieve 
80% power with an α = 0.05 for the primary com-
posite outcome.
Descriptive statistics were used to summarize cat-
egorical variables as percentages and continuous 
variables as medians (interquartile ranges). 
Independent samples were compared using the 
chi-square test or Wilcoxon rank-sum test as 
appropriate. Given the relatively high frequency 
of death anticipated from studying critically ill 
patients, we analyzed time to ICU discharge from 
vancomycin initiation with a competing-risks 
regression approach using the methods of Fine 
and Gray16 with death as a competing event and 
displayed graphically with a cumulative incidence 
function. Analysis of clinical failure by primary 
infection site (isolated bacteremia or pneumonia) 
between the loading dose and no loading dose 
groups was a pre-planned secondary analysis. 
Exploratory analyses of the primary outcome 
included the reconstruction of the loading dose 
variable in quartiles rather than a dichotomous 
variable, and evaluation of initial doses of 
⩾1750 mg versus <1750 mg as hypothesized by 
other research groups to have benefit.10 We built 
a multivariable logistic regression model for the 
composite outcome of clinical failure using the 
following pre-specified variables with complete 
data present identified by the study team with the 
potential to influence either the receipt of a load-
ing dose or the outcome of clinical failure at the 
time the vancomycin loading dose was adminis-
tered: vancomycin initial dose (as a continuous 
mg/kg variable), age, sex, MRSA culture site, 
chronic or end-stage renal disease, ICU service, 
day 1 maximum values for WBC, blood urea 
nitrogen, serum creatinine, and temperature, 
SOFA score, need for vasopressor support, or 
need for mechanical ventilation. The PBS was 
not included due to presumed collinearity with 
SOFA and other variables included. Variance 
inflation factors were used to assess collinearity 
and ensure all variables were appropriate to retain 
in the model. Statistical analyses were performed 
in Stata (StataCorp. 2019. Stata Statistical 
Software: Release 16. College Station, TX, USA: 
StataCorp LLC) and SAS (SAS Institute Inc., 
Cary, NC, USA). Statistical significance was set 
at p < 0.05.
Results
As shown in Figure 1, 871 patients were identi-
fied as having an ICU admission with a concur-
rent positive culture for MRSA during the 
specified ICU admission. Following application 
of the exclusion criteria, 449 patients were avail-
able for analysis. Of these patients, 103 (22.9%) 
received a loading dose while 346 (77.1%) did 
not. Patient demographics for the cohort are 
shown in Table 1. The cohort consisted primarily 
Therapeutic Advances in Infectious Disease 8
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of patients on medical services with approxi-
mately half of MRSA cases isolated from respira-
tory cultures. Approximately three-quarters of the 
cohort required mechanical ventilation and one-
third required vasopressor support at the time of 
vancomycin initiation. Patients were well-
matched in terms of baseline characteristics 
between the two groups. Patients in the loading 
dose group received higher initial doses on a mil-
ligram [1500 (1250–1750) versus 1250 (1000–
1500); p < 0.001] and a milligram per kilogram 
actual body weight basis [21 (20–22) versus 16 
(15–18); p < 0.001] compared with the no load-
ing dose group. Patients classified as receiving a 
loading dose tended to weigh less than patients in 
the no loading dose group [68 (61–85) kg versus 
80 (66–97) kg; p < 0.001]. Only one patient 
received an initial vancomycin dose greater than 
2 g. All patients were administered vancomycin 
via intermittent infusion.
There was no difference in the percentage of 
patients experiencing clinical failure between the 
loading dose and no loading dose groups (74.8% 
versus 72.8%; p = 0.698), with no significant dif-
ference between groups in any component of the 
composite outcome (Table 2). No differences 
were noted between groups in any of the second-
ary outcomes, including all-cause ICU mortality, 
AKI, or duration of vasopressor or mechanical 
ventilatory support. The first serum vancomycin 
trough concentration was slightly higher in the 
loading dose group, but this did not reach 
statistical significance [15.6 (11.0–24.4) µg/ml 
versus 14.0 (9.5–21.0) µg/ml; p = 0.056]. There 
were no differences in WBC or maximum tem-
perature on days 2–5 following the initiation of 
vancomycin (Supplemental material eTable 1 
online; Figure 2). In a simple competing risk 
regression model with death as a competing 
event, use of a loading dose was not associated 
with time to ICU discharge from vancomycin ini-
tiation (subdistribution hazard ratio 1.09; 95% 
confidence interval 0.86–1.40). The cumulative 
incidence function is shown in Supplemental 
eFigure 1. In the subgroup of patients with iso-
lated MRSA bacteremia, there was no difference 
in clinical failure between the loading dose and no 
loading dose groups: 30/34 (88.2%) versus 63/80 
(78.8%); p = 0.232. Similarly, in patients with 
MRSA respiratory cultures (with or without bac-
teremia), there were no differences between load-
ing dose and no loading dose groups: 47/69 
(68.1%) versus 188/265 (70.9%); p = 0.647.
In exploratory analyses of the primary outcome, 
the vancomycin dose (in milligrams per kilogram 
actual body weight) was assessed in quartiles 
rather than a dichotomous variable and there 
were no significant differences in the frequency of 
clinical failure (p = 0.794; Supplemental eTable 2). 
Similarly, when initial doses of ⩾1750 mg were 
compared with doses <1750 mg, there was no 
difference in clinical failure between the two 
groups (p = 0.485; Supplemental eTable3). In the 
adjusted multivariable logistic regression model, 
Figure 1. Application of inclusion and exclusion criteria.
ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus.
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Table 1. Baseline demographics.





Age, years 54 (38–66) 57 (45–68) 0.102
Sex (% male) 58 (56.3) 198 (57.2) 0.869
Culture site 0.099
 Blood (%) 34 (33.0) 80 (23.2)  
 Respiratory (%) 55 (53.4) 199 (57.7)  
 Both (%) 14 (13.6) 66 (19.1)  
Chronic kidney disease (%) 8 (7.8) 41 (11.9) 0.243
End stage renal disease (%) 7 (6.8) 23 (6.7) 0.958
Service (% medical) 80 (77.7) 234 (67.6) 0.051
Minimum inhibitory concentration, µg/mla 1 (1–1) 1 (1–1) 0.352
Long term indication for MRSA treatmentb (%) 12 (11.7) 25 (7.2) 0.216
Weight, kg 68 (61–85) 80 (66–97) <0.001
Initial vancomycin dose, mg 1500 (1250–1750) 1250 (1000–1500) <0.001
Initiatial vancomycin dose, mg/kg actual body 
weight
21 (20–22) 16 (15–18) <0.001
Number of concurrent nephrotoxins within first 
5 days
1 (0–2) 1 (1–2) 0.441
Vancomycin therapy duration, days 6 (3–12) 6 (3–11) 0.843
At time of vancomycin initiation
 White blood cell count, ×103/mm3 15 (10–21) 13 (9–19) 0.150
 Blood urea nitrogen, mg/dl 23 (15–41) 26 (15–41) 0.625
 Serum creatinine, mg/dl 1.1 (0.7–1.6) 1.0 (0.7–1.7) 0.902
 Maximum temperature, °F 100.4 (98.7–102.0) 100.7 (99.3–102.3) 0.101
 Sequential organ failure assessment score 8 (5–10) 7 (5–10) 0.674
 Pitt bacteremia score 5 (4–7) 5 (3–7) 0.607
 Requirement for vasopressor support (%) 31 (30.1) 105 (30.4) 0.961
 Mechanical ventilation (%) 77 (74.8) 254 (73.6) 0.818
 Lactate, mmol/lc 1.8 (1.1–3.3) 1.6 (1.1–3) 0.586
aAvailable for 295 patients.
bLong-term indication defined as ⩾4 weeks of therapy.
cAvailable for 366 patients.
MRSA, methicillin-resistant Staphylococcus aureus.
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the first dose of vancomycin (expressed in milli-
grams per kilogram as a continuous variable) was 
not associated with clinical failure: odds ratio 
0.98 (95% confidence interval 0.91–1.06) 
(Supplemental eTable 4).
Discussion
This represents the first study to our knowledge 
to assess clinical outcomes associated with vanco-
mycin loading doses recommended by consensus 
guidelines in critically ill patients with MRSA 
infection,7 and the largest study of vancomycin 
loading doses in any patient population. While 
the ideal design to answer this clinical question is 
a randomized controlled trial, given the literature 
that every hour delay in antibiotics in a patient 
with sepsis is associated with a 7.6% reduction in 
survival,17 including similar literature in S. aureus 
bacteremia specifically,18 obtaining informed 
consent during this window for a definitively large 
study in critically ill patients is likely to hinder 
such a trial ever being done, particularly for con-
firmed MRSA infection rather than all patients 
receiving empiric vancomycin.
A randomized controlled trial of vancomycin 
loading doses in the emergency department 
showed that a loading dose of 30 mg/kg versus 
15 mg/kg resulted in higher trough values at 12 
and 24 h, but not by 36 h, with no significant dif-
ference in AKI or clinical outcomes between the 
two groups.19 Similarly, other observational stud-
ies have shown an association between loading 
doses and higher target attainment of initial 
trough values without increasing the risk of 
AKI,20,21 although improved target trough attain-
ment is not consistent across the literature.11,22 







 Clinical failure (%) 77 (74.8) 252 (72.8) 0.698
 Death within 30 days (%) 20 (19.4) 77 (22.3) –
 Blood cultures positive ⩾7 days (%) 12 (11.7) 16 (4.6) –
 WBC count >12 × 103/mm3 after 5 days (%) 28 (27.2) 93 (26.9) –
 Persistent temperature >100.4°F after 5 days (%) 8 (7.8) 36 (10.4) –
 Substitution/addition of alternative treatment (%) 9 (8.7) 30 (8.7) –
Secondary outcomes
 All-cause mortality in ICU (%) 21 (20.4) 87 (25.1) 0.321
 Time from vancomycin initiation to ICU discharge, days 9.4 (4.4–16.7) 9.5 (4.9–17.4) 0.880
  Acute kidney injury within 5 days of vancomycin 
initiation (%)a
20 (20.2) 59 (17.8) 0.765
 Duration of vasopressor support, daysb 3 (2–5) 3 (2–6) 0.793
 Duration of mechanical ventilation, daysc 8.5 (4.3–17) 9 (4–20) 0.632
 First vancomycin serum trough concentration, µg/mld 15.6 (11.0–24.4) 14.0 (9.5–21.0) 0.056
aPatients with end stage renal disease excluded from assessment.
bAvailable for the 136 patients requiring vasopressor support at vancomycin initiation.
cAvailable for the 331 patients requiring mechanical ventilation at vancomycin initiation.
dAvailable for 361 patients.
ICU, intensive care unit; WBC, white blood cell.
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Similar to other studies, we did not observe any 
increased risk of AKI with use of a vancomycin 
loading dose.19,20 Particularly with updated con-
sensus guidelines recommending AUC assessment 
at this juncture rather than trough assessment,7 the 
existing literature linking vancomycin loading 
doses to trough attainment as justification for use 
of a particular dosing strategy deserves reevalua-
tion. Thus, there is an increasing importance to 
evaluate clinical outcomes regarding the decision 
to administer a loading dose.
One small cohort study found an association of 
vancomycin loading doses (⩾20 mg/kg) with clin-
ical response, as defined by survivors with a 
⩾30% reduction in WBC count or C-reactive 
protein, or decline in fever over 48–72 h; how-
ever, the number of MRSA cases from the cohort 
studied was relatively small.11 In a larger study of 
MRSA bacteremia, loading doses (⩾20 mg/kg) 
were not associated with treatment failure; how-
ever, in a post-hoc analysis where loading doses 
were reclassified as ⩾1750 mg, a protective effect 
of loading doses was noted.10 In both studies, 
loading doses were not associated with nephro-
toxicity.10,11 Of note, critically ill patients were 
not the focus of these prior studies, and ICU 
patients constituted approximately 25% of the 
cohort.10 Our study did not find a benefit of load-
ing doses on any of the distinct outcomes that we 
included in the primary composite outcome, nor 
when assessed by site of infection as a subgroup 
analysis. Similarly, there was no signal of benefit 
noted in the sensitivity analysis examining 
quartiles of loading doses, the reclassification of 
loading doses as 1750 mg or higher, or in the mul-
tivariable logistic regression model evaluating ini-
tial dose on a milligrams per kilogram basis as a 
continuous variable.
As noted previously, a recent survey of vancomy-
cin dosing practices in critically ill patients 
revealed that a lack of clinical outcome data, con-
cerns of nephrotoxicity, and time delay of admixed 
custom doses from the pharmacy (in the case of a 
loading dose) versus pre-mixed drug from auto-
mated dispensing cabinets limited application of 
loading doses in all cases.8 Our data suggest load-
ing doses of vancomycin do not increase the risk 
of AKI, even in critically ill patients with multiple 
risk factors for AKI. However, the data also sug-
gest no clinical benefit of loading doses even in 
confirmed MRSA infections in critically ill 
patients, thus supporting the noted clinician hesi-
tation. Indeed, given the increase in mortality 
with every hour delay in antibiotic therapy,17,18 
our study supports the notion that therapy should 
not be delayed for dose customization to meet the 
specified loading dose criteria. This finding not 
only applies to emergency departments, post-
anesthesia care units, and other ICU triage areas 
in resource-intensive healthcare settings, but may 
also be a relevant consideration to care provisions 
in lower resource-intensive settings where dose 
customization for loading doses may be limited. 
Although the mechanistic explanation of our 
findings is less clear for patients with bacteremia, 
the relatively poor ability of vancomycin to 
Figure 2. Daily white blood cell count and temperature trends.
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concentrate in pulmonary tissue, particularly after 
a single dose, may explain the lack of difference in 
clinical outcomes observed in our study.23 
Additionally, considering the literature associat-
ing a delay in second dose of antibiotics for 
patients admitted from the emergency depart-
ment with sepsis with outcomes including mortal-
ity,24 our study suggests that the initial, loading 
dose of vancomycin may not significantly influ-
ence clinical outcomes in critically ill patients, 
and a greater emphasis be placed on ensuring 
timely initiation of subsequent doses to ensure 
appropriate efforts to attain goal AUC:MIC tar-
gets for the initial 24 h period.
Strengths of our study included the large sample 
size, which was sufficiently powered to determine 
differences in clinical failure. We built on previ-
ous literature by studying only confirmed cases of 
MRSA and expanding on the study of pharma-
cokinetic outcomes to clinical outcomes of this 
patient population. Our definition of clinical fail-
ure has been used in other studies of MRSA 
infection and all components are measured objec-
tively, thus not relying on subjective assessments 
such as clinical resolution.10,11 Anticipating that 
detecting a difference in an outcome such as ICU 
length of stay or vasopressor duration would 
require several-fold additional patients, the out-
come of clinical failure is sensitive to surrogate 
outcomes such as WBC and temperature changes 
over time that may have seen more immediate 
effects from the loading dose, if present. The two 
groups of patients were similar in terms of sever-
ity of illness, kidney disease, and other pre-identi-
fied factors that might have predisposed to receipt 
of a loading dose or clinical outcome. We also 
included multiple types of infections commonly 
afflicting critically ill patients.
Our study also has noted limitations, including 
the retrospective, non-randomized, and single 
center design. Due to vancomycin dosing prac-
tices at the institution, we are not able to make 
any inferences about the clinical benefits of load-
ing doses beyond 2000 mg as only one patient 
received a >2000 mg loading dose. However, a 
dose cap of 2000 mg was the most commonly 
reported dose cap in a prior study of vancomycin 
dosing practices among critical care pharmacists, 
suggesting this practice is widespread.8 Relevant 
to this study, any patient over 100 kg was there-
fore essentially ineligible to be categorized as 
having received a loading dose. Accordingly, 
whether or not relatively larger loading doses (up 
to 3000 mg as maximally defined in current con-
sensus guidelines)7 are associated with any clini-
cal benefit remains unknown at this time, although 
the lack of dose response noted in the exploratory 
analysis of loading dose by quartiles would sug-
gest against this. Our study design also excluded 
patients weighing ⩾125 kg, thus our results may 
not be directly applicable to obese patients. The 
difference in the initial vancomycin dose between 
the loading dose and no loading dose cohorts was 
not as drastic as would have been the case if 
higher loading doses were used in our study. The 
loading dose group received an additional 5 mg/
kg (or 250–500 mg typically). While dichotomiza-
tion of information can have drawbacks, use of a 
loading dose or not is typically a dichotomous 
decision clinically. Additionally, the lack of signal 
in the quartile analysis and in the multivariable 
regression where initial dose was analyzed as a 
continuous variable supports the findings that ini-
tial dose does not appear to impact clinical fail-
ure. We also did not estimate or measure 
vancomycin AUC in these groups as a result of 
the loading dose, or in subsequent dosing inter-
vals, and thus are unable to directly compare van-
comycin AUC with these clinical outcomes. The 
known variability in vancomycin pharmacokinet-
ics in critically ill patients makes it possible that 
patients in this study may have not achieved ade-
quate AUC with the loading doses, thus explain-
ing the lack of clinical benefit observed. For 
example, a significant number of these patients 
may have had AKI upon admission or been 
actively fluid resuscitated at the time of vancomy-
cin loading dose, which would have increased the 
Vd and may have influenced the ability to achieve 
the target exposure with the vancomycin doses 
observed in the study. More patients had respira-
tory infections than bacteremia, thus if there was 
a differential effect of loading doses given the site 
of infection, we may have been underpowered to 
detect it. Finally, although patients appeared to 
be well-matched based on identified characteris-
tics, we cannot rule out residual confounding and 
its effects.
Conclusion
In critically ill patients with MRSA infection cul-
tured from the blood or respiratory tract, receipt 
of a loading dose of vancomycin (⩾20 mg/kg 
AH Flannery, KL Wallace et al.
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actual body weight) was not associated with any 
differences in clinical failure, mortality, ICU 
length of stay, AKI, or other outcomes when com-
pared with patients not receiving a loading dose.
Author contributions
AF conceived the concept, designed the study, 
analyzed the data, and wrote the first draft of the 
manuscript. KW, DB, AC, and PM assisted with 
the design of the study. CR, AO, RM, SP assisted 
with data acquisition, analysis, and data visualiza-
tion. All authors contributed to review of the 
manuscript, added important intellectual contri-
butions, and approved of the final version.
Conflict of interest statement
The authors declare that there is no conflict of 
interest.
Funding
This research received no specific grant from any 
funding agency in the public, commercial, or not-
for-profit sectors.
ORCID iD
Alexander H. Flannery  https://orcid.org/0000- 
0003-2933-1594
Supplemental material
Supplemental material for this article is available 
online.
References
 1. Wisplinghoff H, Bischoff T, Tallent SM,  
et al. Nosocomial bloodstream infections in 
US hospitals: analysis of 24,179 cases from a 
prospective nationwide surveillance study. Clin 
Infect Dis 2004; 39: 309–317.
 2. Blot SI, Vandewoude KH, Hoste EA,  
et al. Outcome and attributable mortality in 
critically ill patients with bacteremia involving 
methicillin-susceptible and methicillin-resistant 
Staphylococcus aureus. Arch Intern Med 2002; 162: 
2229–2235.
 3. Chastre J and Fagon JY. Ventilator-associated 
pneumonia. Am J Respir Crit Care Med 2002; 
165: 867–903.
 4. Lodise TP, Drusano GL, Zasowski E,  
et al. Vancomycin exposure in patients with 
methicillin-resistant Staphylococcus aureus 
bloodstream infections: how much is enough? 
Clin Infect Dis 2014; 59: 666–675.
 5. Roberts JA and Lipman J. Pharmacokinetic issues 
for antibiotics in the critically ill patient. Crit Care 
Med 2009; 37: 840–851; quiz 59.
 6. del Mar Fernández de Gatta Garcia M, 
Revilla N, Calvo MV, et al. Pharmacokinetic/
pharmacodynamic analysis of vancomycin in ICU 
patients. Intensive Care Med 2007; 33: 279–285.
 7. Rybak MJ, Le J, Lodise TP, et al. Therapeutic 
monitoring of vancomycin for serious methicillin-
resistant Staphylococcus aureus infections: a 
revised consensus guideline and review by the 
American Society of Health-System Pharmacists, 
the Infectious Diseases Society of America, the 
Pediatric Infectious Diseases Society, and the 
Society of Infectious Diseases Pharmacists. Am J 
Health Syst Pharm 2020; 77: 835–864.
 8. Flannery AH, Hammond DA, Oyler DR, et al. 
Vancomycin dosing practices among critical care 
pharmacists: a survey of society of critical care 
medicine pharmacists. Infect Dis (Auckl) 2020; 
13: 1178633720952078.
 9. Shorr AF, Zilberberg MD, Micek ST, et al. 
Outcomes associated with bacteremia in the 
setting of methicillin-resistant Staphylococcus 
aureus pneumonia: a retrospective cohort study. 
Crit Care 2015; 19: 312.
 10. Ortwine JK, Zasowski EJ, Pogue JM, et al. 
Relationship status between vancomycin loading 
dose and treatment failure in patients with MRSA 
bacteremia: it’s complicated. Infect Dis Ther 2019; 
8: 627–640.
 11. Ueda T, Takesue Y, Nakajima K, et al. 
Vancomycin loading dose is associated with 
increased early clinical response without 
attainment of initial target trough concentration 
at a steady state in patients with methicillin-
resistant Staphylococcus aureus infections.  
J Clin Pharm Ther 2020; 45: 682–690.
 12. Kellum JA, Lameire N, Aspelin P, et al. Kidney 
Disease: Improving global outcomes (KDIGO) 
acute kidney injury work group. KDIGO clinical 
practice guideline for acute kidney injury. Kidney 
Int Suppl 2012; 2: 1–138.
 13. Vincent JL, Moreno R, Takala J, et al. The SOFA 
(Sepsis-related Organ Failure Assessment) score 
to describe organ dysfunction/failure. On behalf 
of the working group on sepsis-related problems 
of the European Society of Intensive Care 
Medicine. Intensive Care Med 1996; 22: 707–710.
 14. Chow JW and Yu VL. Combination antibiotic 
therapy versus monotherapy for gram-negative 
bacteraemia: a commentary. Int J Antimicrob 
Agents 1999; 11: 7–12.
Therapeutic Advances in Infectious Disease 8
10 journals.sagepub.com/home/tai
 15. Henderson H, Luterbach CL, Cober E, et al. 
The Pitt bacteremia score predicts mortality in 
nonbacteremic infections. Clin Infect Dis 2020; 
70: 1826–1833.
 16. Fine JP and Gray RJ. A proportional hazards 
model for the sub-distribution of a competing 
risk. J Am Stat Assoc 1999; 94: 496–509.
 17. Kumar A, Roberts D, Wood KE, et al. Duration 
of hypotension before initiation of effective 
antimicrobial therapy is the critical determinant 
of survival in human septic shock. Crit Care Med 
2006; 34: 1589–1596.
 18. Corl KA, Zeba F, Caffrey AR, et al. Delay in 
antibiotic administration is associated with 
mortality among septic shock patients with 
Staphylococcus aureus bacteremia. Crit Care Med 
2020; 48: 525–532.
 19. Rosini JM, Laughner J, Levine BJ, et al. A 
randomized trial of loading vancomycin in the 
emergency department. Ann Pharmacother 2015; 
49: 6–13.
 20. Golenia BS, Levine AR, Moawad IM, et al. 
Evaluation of a vancomycin dosing nomogram 
based on the modification of diet in renal disease 
equation in intensive care unit patients. J Crit 
Care 2013; 28: 710–716.
 21. Truong J, Levkovich BJ and Padiglione AA. 
Simple approach to improving vancomycin 
dosing in intensive care: a standardised loading 
dose results in earlier therapeutic levels. Intern 
Med J 2012; 42: 23–29.
 22. Denetclaw TH, Dowling TC and Steinke D. 
Performance of a divided-load intravenous 
vancomycin dosing strategy for critically ill 
patients. Ann Pharmacother 2013; 47: 1611–1617.
 23. Cruciani M, Gatti G, Lazzarini L, et al. 
Penetration of vancomycin into human lung 
tissue. J Antimicrob Chemother 1996; 38: 865–869.
 24. Leisman D, Huang V, Zhou Q, et al. Delayed 
second dose antibiotics for patients admitted 
from the emergency department with sepsis: 
prevalence, risk factors, and outcomes. Crit Care 
Med 2017; 45: 956–965.
Visit SAGE journals online 
journals.sagepub.com/
home/tai
SAGE journals
